Filter by Year:
Press Releases
-
Aug 23, 2022
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
-
Aug 17, 2022
Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors
-
Aug 09, 2022
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
-
Aug 01, 2022
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
-
May 31, 2022
Foghorn Therapeutics Announces Upcoming Investor Conference Participation
-
May 19, 2022
Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS
-
May 09, 2022
Foghorn Therapeutics Provides First Quarter 2022 Corporate Update
-
Apr 13, 2022
Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting
-
Apr 01, 2022
Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
-
Mar 11, 2022
Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day
Displaying 31 - 40 of 69